NAKA vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 17, 2026

NAKA

35.3
AI Score
VS
HIVE Wins

HIVE

45.3
AI Score

Investment Advisor Scores

NAKA

35score
Recommendation
AVOID NEW MONEY

HIVE

45score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric NAKA HIVE Winner
Forward P/E 0 62.8931 Tie
PEG Ratio 0 0 Tie
Revenue Growth 8680.1% 73.5% NAKA
Earnings Growth 0.0% -99.9% NAKA
Tradestie Score 35.3/100 45.3/100 HIVE
Profit Margin 0.0% -98.5% NAKA
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD HIVE

Relative Price Performance (Last 90 Days)

NAKA 1M: -21.6% · 3M: +63.1% HIVE 1M: -41.4% · 3M: -34.4%

Current Technical Phase

NAKA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 45

RSI (14): 44.7 · Price: $7.65

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.3%), weak momentum, RSI 24

RSI (14): 23.8 · Price: $1.94

Fundamentals Snapshot

Metric NAKA HIVE
Market Cap — —
Forward P/E -4.0 -3.8
Trailing P/E 4.5 —
Revenue (TTM) — —
Revenue Growth 86.8% 0.7%
Gross Margin -0.4% 0.4%
Operating Margin -0.3% -0.6%
EPS 1.87 -1.32
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.